1 **THE STATE OF CURRENT MANAGEMENT OF THE HEIGHTENED RISK FOR**
2 **ATHEROSCLEROTIC CARDIOVASCULAR EVENTS IN AN ESTABLISHED**
3 **COHORT OF PATIENTS WITH LUPUS ERYTHEMATOSUS**
4 Megan Zhao, BA[1,2], Rui Feng, PhD[3], Victoria P. Werth, MD[1,2*], Kevin Jon Williams, MD[4*]
5
[1]Corporal Michael J. Crescenz Veterans' Administration Medical Center, Philadelphia, PA, USA
[2]Department of Dermatology, University of Pennsylvania, Perelman School of Medicine,
Philadelphia, PA
[3]Department of Biostatistics, University of Pennsylvania, Perelman School of Medicine,
Philadelphia, PA
[4]Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of
Medicine at Temple University, Philadelphia, PA, USA
*Co-senior authors
14

Abstract

Aims: Patients with lupus erythematosus (LE) are at a heightened risk for clinical events, chiefly

heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). To address

this problem, we recently proposed new guidelines for categorization of levels of risk for future

ASCVD events specifically in LE patients, with corresponding recommendations for

management.[1]

Methods and Results: We included all participants in our established UPenn Longitudinal

Lupus Cohort of patients with cutaneous LE, without or with concurrent systemic LE (n=370,

LE-ASCVD Study Cohort, years 2007 to 2021). Of our LE-ASCVD Study Cohort, 336/370

(90.8%) had a designated primary care physician. By the new guidelines, the most recent plasma

low-density lipoprotein cholesterol (LDLc) levels were above goal for 252/370 (68.1%) of the

LE-ASCVD Study Cohort. Of the Study Cohort, 266 (71.9%) had hypertension, which was

under- or un-treated in 198/266 (74.4%). Of current smokers, 51/63 (81.0%) have no chart

documentation of smoking cessation counseling or clinic referral. Diabetes was generally well-

managed, and hypertriglyceridemia was uncommon. Of the LE-ASCVD Study Cohort, 254

patients qualified for two widely used online calculators that estimate the risk of an ASCVD

event in the next 10 years ("10-year ASCVD event risk"): the ACC-ASCVD Risk Estimator Plus

and QRisk3. We also stratified these 254 patients into the categories of ASCVD event risk

defined by Keyes et al. Surprisingly, these three methods for estimating ASCVD event risk

showed clinically meaningful agreement for only 100/254 (39.4%), i.e., discordance for over

60% of LE patients that could affect their clinical management. The actual documented rate of

ASCVD events for patients in the first 10 years after enrollment into the Cohort was 22.3% (95%

CI 16.9%, 27.4%), indicating a high-risk population despite a preponderance of women and a

median age of only 47 years at enrollment.

Conclusion: We conclude that cutaneous LE patients are under-treated compared with the new

guidelines and, accordingly, these patients experience a substantial burden of major adverse

ASCVD events. Moreover, it is unclear how to accurately assess future ASCVD event risk in

cutaneous LE patients – except that it is high – and this uncertainty may complicate clinical

management. Efforts are underway to improve ASCVD event risk estimation and guideline

implementation in lupus patients.

Introduction

Patients with lupus erythematosus (LE) suffer from a heightened risk of clinical events,

chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD).

Several clinical features of LE contribute to the problem.[1] First, patients with LE exhibit an

increased prevalence of conventional risk factors for ASCVD events, particularly

dyslipoproteinemia and hypertension, and glucocorticoid use often exacerbates additional

conditions related to cardiovascular risk, such as obesity, the metabolic syndrome, so-called

"prediabetes" (defined as dysglycemia to an extent that indicates a high risk of developing

diabetes), and type 2 diabetes mellitus.[1, 2] Moreover, patients with cutaneous LE (CLE) smoke at

higher rates than in the general population.[3-5] Second, numerous studies using arterial

ultrasonography, coronary CT angiography, and other methods have shown that LE patients

carry an increased burden of atherosclerotic plaques compared with the general population.[1, 6-9]

Third, the increased rate of ASCVD events amongst LE patients persists even after adjustment

for age and sex and, more strikingly, even after adjustment for other conventional risk factors for

ASCVD events.[1, 10, 11] We have suggested that autoimmune processes specific to LE may

exacerbate specific, known pathogenic steps in atherosclerosis.[1]

Despite their high plaque burden and heightened risk for ASCVD events, however, LE

patients remain undertreated for the causative agents of ASCVD, meaning low-density

lipoprotein (LDL) and other cholesterol-rich apolipoprotein-B (apoB)-containing lipoproteins,[12,

13] and key exacerbators of ASCVD, such as hypertension, smoking, and hyperglycemia.[1, 14-17]

As part of our efforts to address this problem, we recently proposed a system for assessing CLE

and systemic LE (SLE) patients using four defined categories of ASCVD event risk, with

corresponding guidance for clinical management of LE patients in each ASCVD event risk

category using lifestyle modifications and modern medications.[1]

In the current work, we performed a single-center study of all 370 patients with CLE,

without or with concurrent SLE, within our established longitudinal cohort at the University of

Pennsylvania Health System (UPHS) for whom we have full access to their medical records.[18-23]

Our goal was to assess the state of current management of ASCVD event risk through

conventional therapeutic targets, chiefly hyperlipidemia, hypertension, smoking, prediabetes, and

diabetes mellitus, in the light of the new recommendations.[1] We also studied two earlier and still

widely used online tools for estimating the risk of an ASCVD event in the next 10 years ("10-

year ASCVD event risk"): the American College of Cardiology (ACC) ASCVD Risk Estimator

Plus[24, 25] and the QRisk3 calculator.[26-28]

Methods

The LE-ASCVD Study Cohort

We previously reported the UPenn Longitudinal Lupus Cohort, which is our established

cohort of patients receiving care at UPHS whom we have been recruiting from our specialty

Dermatology clinic since 2007 based on a diagnosis of CLE, without or with concurrent SLE.[18-

23] The UPHS Institutional Review Board approved patient recruitment and then collection and

analyses of data, and we obtained written informed consent from each participant.

For the current study, we required full access to longitudinal and recent medical records.

Thus, we included only active UPHS patients and patients whose records from outside hospitals

were either linked or faxed into the UPHS electronic medical record ("LE-ASCVD Study

Cohort"). Our database consisted of clinical information for these patients, including ASCVD

events and parameters relevant to management of future ASCVD event risk, that we entered into

the University's secure RedCap system (Research Electronic Data Capture, Vanderbilt

University, Nashville, TN, USA) to ensure compliance with confidentiality requirements of the

Health Insurance Portability and Accountability Act of 1996 (HIPAA).

Demographic and clinical data collected for the RedCap database

Demographic and clinical data collected for the LE-ASCVD Study Cohort included sex,

race/ethnicity, age at enrollment, age as of 2021, time since enrollment in our cohort, time since

CLE diagnosis, whether there was also a diagnosis of SLE, and, if so, time since SLE diagnosis.

When simultaneous heights and weights were available, we calculated body mass indices

(BMIs), to stratify the patients into categories of underweight (commonly defined as <18.5 kg/m^2

but alternatively as <20.0 kg/m^2 based on mortality data[29]), normal weight (commonly defined

as 18.5 to 24.9 kg/m^2 but also as 20.0 to 24.9 kg/m^2),[29] overweight (25.0 to 29.9 kg/m^2), or

obese (≥30.0 kg/m^2). Amongst the LE-ASCVD Study Cohort, a diagnosis of depression in the

electronic medical record, history of lupus nephritis, history of chronic kidney disease (CKD)

stage 3 or higher, and smoking status (never, former, or current) from chart abstraction were also

entered into our RedCap database.

In our RedCap database, we also included whether there was a listed primary care

provider (PCP), and the date of the last PCP visit was noted. All specialties caring for the

patients within the past 20 years, if available, were compiled.

Orders and results for lipid/lipoprotein panels and glycated hemoglobin (HbA$_{1c}$) levels

were extracted from the electronic medical records, including dates and the specialty of the

ordering physician. Lipid/lipoprotein panels typically did not include a full set of conventional

values, meaning plasma concentrations of total cholesterol (TC), LDL cholesterol (LDLc),

triglycerides (TG), high-density lipoprotein cholesterol (HDLc), apolipoprotein-B (apoB), and a

one-time assay for lipoprotein(a) [Lp(a)];[1, 30-32] thus, our tabulations often show an n less than

the full LE-ASCVD Study Cohort. Non-HDLc, a convenient parameter that captures the

cholesterol carried by LDL and all other atherogenic apoB-lipoproteins, was calculated as TC

minus HDLc. All blood pressure values in each patient's chart were entered into our RedCap

database, to allow us to assess recent blood pressure management and to calculate blood pressure

variability, a parameter included in the QRisk3 calculator. Hypertension was defined as a

systolic blood pressure ≥130, a diastolic pressure ≥80 mm Hg, and/or on anti-hypertensive

medication, following the recently updated joint guidelines from the ACC and the American

Heart Association (AHA).[17, 33] We averaged blood pressure readings from the most recent year

of follow-up.

Following criteria from the American Diabetes Association (ADA), HbA_{1c} values of 5.7-

6.4% indicate prediabetes, and $HbA_{1c} \geq 6.5\%$ is diagnostic for diabetes mellitus.[34] Accordingly,

prediabetes was defined here as chart-diagnosed or the most recent HbA_{1c} was 5.7-6.4%, without

a diagnosis of overt diabetes on the chart. Diabetes was defined as chart-diagnosed or the most

recent HbA_{1c} was $\geq 6.5\%$. The most recent HbA_{1c} value for some patients with a diagnosis of

diabetes mellitus was below 6.5%; we still classified them under diabetes unless a clinician had

marked the diagnosis on the chart as resolved or in remission. For patients with diabetes, HbA_{1c}

values $\leq 7\%$ indicate that the condition is well-controlled.[34-38]

Documentation in the electronic charts of counseling on lifestyle changes, specifically

diet, exercise, weight loss, and smoking cessation, was noted along with dates of counseling.

Referrals to dieticians, weight-loss programs, and smoking cessation clinics were also included.

From physicians' and other providers' notes and the medication lists in the charts, we extracted

prescriptions for medications for lipid-lowering, hypertension, and glycemic control, as well as

the dates of these prescriptions.

All previously documented or newly incident major adverse atherosclerotic

cardiovascular events (MAACE) were noted along with the event date and were defined as

atherosclerotic myocardial infarction (MI), atherosclerotic ischemic heart disease other than MI

such as angina and coronary revascularization, atherosclerotic (non-embolic) ischemic stroke or

transient cerebrovascular ischemic attack, newly diagnosed symptomatic peripheral arterial

disease (PVD), or hospitalization for chest pain, shortness of breath, or palpitations with

suspicion of ischemic origin. Major adverse cardiovascular events (MACE) that were clearly not

atherosclerotic were excluded, such as coronary vasospasm without documentation of nearby

plaque, embolic stroke unrelated to atherosclerosis, and heart failure from non-ischemic causes

(chronic hypertension, diabetes mellitus, non-ischemic valvular disorders, post-myocarditis, and

congenital or genetic defects).

Three systems to estimate the risk of a future ASCVD event for individual patients within the LE-

ASCVD Study Cohort

Based on these clinical data, including absence or presence of clinically evident ASCVD

and major conventional risk factors for ASCVD events, we classified patients from the LE-

ASCVD Cohort into the four defined categories of ASCVD event risk from our recently

proposed guidelines for ASCVD event risk management for LE patients[1] – namely, High Risk,

Very High Risk, Extreme Risk, and Recent Recurrent ASCVD Events. Next, we compared

current clinical care with the new therapeutic goals for each of these categories of ASCVD event

risk for LE patients.[1]

In addition, we evaluated patients in the LE-ASCVD Cohort with two widely used online

calculators that estimate 10-year ASCVD event risk for individuals from the general population,

i.e., not specifically designed for CLE patients. Use of these online calculators was limited to

patients with sufficient data in the electronic chart and no clinically evident ASCVD (primary

prevention); the calculators are not designed to estimate future ASCVD event risk in patients

who have already had an atherosclerotic cardiovascular event (secondary prevention). One of

the online calculators that we used was the ACC ASCVD Risk Estimator Plus, which may be the

best known but does not take a diagnosis of LE into consideration.[24, 25] Moreover, it calculates

10-year ASCVD event risk only for patients aged 40-79 years. To allow calculations as broadly

as possible, patients in our LE-ASCVD Cohort below age 40 years without clinically evident

ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus were scaled

up to 40, and patients above age 79 years without clinically evident ASCVD were scaled down

to 79. For simplicity, we did not include multipliers of this estimation of 10-year ASCVD event

risk, although some authors have advocated such multipliers for LE patients.[1, 39] There were just

two patients with TC >320 mg/dL, the highest value allowed by the ACC ASCVD Risk

Estimator Plus, so we scaled those values to 320. We stratified LE patients by their estimated 10-

year ASCVD event risks from the ACC Risk Estimator Plus, following the cutoffs of Arnett et

al. in the ACC/AHA guidelines for primary prevention in the general population[25] – namely,

0.0-4.9% 10-year ASCVD event risk (low), 5.0-7.4% (borderline), 7.5-19.9% (intermediate), and

≥20% (high).

The other online calculator that we used to estimate 10-year ASCVD event risk was

QRisk3, which includes SLE status and use of orally administered steroids, but not CLE status,

and requires that patients not be prescribed statins at baseline.[26, 27] QRisk3 can be used for

patients aged 25-84 years, so we scaled up three patients to an age of 25 and scaled down four

patients to an age of 84. The QRisk3, which is based in the United Kingdom, draws on data for

specific racial/ethnic groups there that do not include large numbers of African Americans or

Hispanics, and so patients from our LE-ASCVD Cohort in those demographics had to be

classified under the QRisk3 category of "Other ethnic group". The ACC ASCVD Risk

Estimator Plus, which is based in the USA and therefore more aligned with the population of our

catchment area, does not have this limitation. Online estimates were performed by one author

(MZ), and divergent estimates of 10-year event risk between the two online calculators were

spot-checked by another author (KJW).

Statistical analyses

Categorical parameters are given as n (%). Continuous variables are given as mean±SD,

if normally distributed, or as median (interquartile range, IQR), if non-normally distributed.

We used several approaches to compare the three systems to estimate the risk of a future

ASCVD event in this Cohort – namely, the categories of ASCVD event risk for LE patients from

Keyes et al.[1] and the two widely used online calculators that estimate 10-year ASCVD event

risk in primary prevention.[24, 28] To assess the correlation between the numerical estimates of 10-

year ASCVD event risk from the QRisk3 versus the ACC Risk Estimator Plus for all patients in

the LE-ASCVD Study Cohort for whom we could use both, we calculated a Pearson's

correlation coefficient (r) and fit a linear regression.

To compare the two online calculators with the newly proposed categories of ASCVD

event risk for LE patients from Keyes et al., we used the key cutoff of 7.5% estimated 10-year

ASCVD event risk from Arnett et al.'s ACC/AHA guidelines for primary prevention in the

general population.[25] In those guidelines, estimates of 10-year ASCVD event risk ≥7.5% come

with substantially more aggressive recommendations for management compared with the

recommendations for patients with estimates of 10-year ASCVD event risk <7.5%.[25]

Thus, we defined clinically meaningful agreement amongst the three methods as

classification of an LE patient into the "High Risk" or "Very High Risk" categories of primary

prevention from Keyes et al., along with estimates of 10-year ASCVD event risk ≥7.5% from

both of the online calculators. Clinically significant discordance between the two online

calculators meant estimates of 10-year ASCVD event risk for an LE patient that were <7.5%

from one calculator but ≥7.5% from the other. Discordance between the categories of Keyes et

al. versus both of the online risk estimators occurred in patients who were at High or Very High

Risk according to Keyes et al., yet both online calculators gave estimates of 10-year ASCVD

event risk <7.5%.

Documented major adverse atherosclerotic cardiovascular events (MAACE) were

tabulated for the period before enrollment into the Cohort and then for the entire period of study

after enrollment. Event-free survival rates since enrollment in the LE-ASCVD Study Cohort

were computed according to Kaplan & Meier, along with 95% confidence intervals.[40, 41] The

actual documented rate of ASCVD events for patients in the first 10 years after enrollment into

the LE-ASCVD Study Cohort was calculated as one minus the event-free survival rate at the 10-

year time point of the Kaplan-Meier survival curve.

This study followed the principles outlined in the Declaration of Helsinki.

Results

The UPenn Longitudinal Lupus Cohort currently consists of 529 CLE patients.[21-23] Upon

review, we found that 370 of them have electronic medical records that are fully accessible

within UPHS and therefore could be included in our LE-ASCVD Study Cohort.

Table 1 shows demographics and other characteristics of the LE-ASCVD Study Cohort.

Consistent with our previous reports,[1, 21, 23] the LE-ASCVD Study Cohort was predominantly

female (82.4%), with nearly nine out of 10 identifying as White (51.4%) or Black (38.1%),

consistent with the UPHS catchment area. Average age was 47.1±14.9 years at enrollment and

54.8±15.9 years at the end of the data collection period (Table 1). Average length of time since

enrollment into the UPenn Longitudinal Lupus Cohort was 7.7±4.5 years.

As of their most recent medical encounter, 22.2% of the patients in our LE-ASCVD

Study Cohort had clinically evident ASCVD, meaning a diagnosis of MAACE as defined in the

Methods, which classifies these individuals as candidates for secondary prevention (n=82/370;

Extreme Risk in Table 1 and in Figure 1A; no patient qualified for the highest-risk category from

Keyes et al. of Recent Recurrent ASCVD Events). Just over half of the LE-ASCVD Study

Cohort had concurrent SLE (51.4%), with 11.4% having a history of lupus nephritis, and 10.0%

having a history of stage 3 or 4 CKD. Median times since diagnosis of CLE or concurrent SLE

were over a decade (Supplementary Table S1). Almost three-quarters of the patients in the LE-

ASCVD Study Cohort (71.9%) had hypertension, 29.5% were former smokers, and 17.0% are

current smokers (Table 1). Of the subgroup with at least one set of simultaneous height and

weight measurements, approximately one-third were underweight or normal weight (n=125/346,

36.2%), one-third overweight (30.3%), and one-third obese (33.5%; Table 1 and Supplementary

Table S1). Prediabetes was present in 18.1%, and diabetes in 10.5%, of the LE-ASCVD Study

Cohort (Table 1). A diagnosis of depression was common (37.6%; Supplementary Table S1), as

previously reported for CLE.[42]

Regarding management, nearly all the patients in the LE-ASCVD Study Cohort had a

primary-care physician listed in the electronic medical record (90.8%; Table 1). Time elapsed

since the last visit with a primary-care physician was 10 months (IQR 4.0-31; Supplementary

Table S1). Number of physician providers, excluding trainees, was 5.8±2.8 per patient

(mean±SD; Supplementary Table S1). Most patients in the Study Cohort had seen a

rheumatologist (203/307, 54.9%), and under half had seen a cardiologist (40.8%), nephrologist

(15.4%), or endocrinologist (8.0%; Supplementary Table S1).

Assessments and management of lipid/lipoprotein levels as targets to lower ASCVD event risk

The vast majority (n=325/370, 87.8%) of patients in the LE-ASCVD Study Cohort had

plasma lipid/lipoprotein levels checked at least once, with a median elapsed time of 35 months

(IQR 14-83) since the most recent panel, i.e., almost three years (Supplementary Table S1). We

found that PCPs checked just over 60% of the most recent lipid/lipoprotein values, and non-

PCPs checked the rest. Of the non-PCPs, rheumatologists checked lipid/lipoprotein values in

more patients than did other subspecialists (Supplementary Table S1).

Using our recently proposed guidelines that we tailored specifically for lupus patients,[1]

almost one-quarter of LE patients classified at High Risk for an ASCVD event had plasma LDLc

concentrations that were above the newly recommended ranges (n=11/52, 21.2%; red in the

leftmost column of Figure 1A). More strikingly, over three-quarters of LE patients classified at

either Very High Risk (179/236, 75.8%) or Extreme Risk (62/82, 75.6%) for an ASCVD event

also had plasma LDLc concentrations above the newly recommended ranges (red in the middle

two columns of Figure 1A). For the 252 LE patients whose most recent LDLc value was above-

goal, the time elapsed since that above-goal LDLc was 47 months (IQR 24-97), i.e., almost four

years (Supplementary Table S1). Data for non-HDLc levels were similar: 13.5% (7/52), 66.5%

(157/236), and 72.0% (59/82) of our LE patients in these three categories of ASCVD event risk

had values above the newly recommended ranges (Supplementary Figure S1A).

Regarding lipid/lipoprotein management in primary prevention, 90.9% (n=10/11) of High

Risk patients with out-of-range LDLc levels were not on any LDL-lowering medications

recorded in their charts, and 70.4% (n=126/179) of Very High Risk patients with out-of-range

LDLc levels were not on LDL-lowering medications (Figure 1B). Again, data for non-HDLc

levels were similar: 85.7% (6/7), and 72.6% (114/157) of LE patients in these two categories of

ASCVD event risk with out-of-range non-HDLc levels were not on any LDL-lowering

medications (Supplementary Figure S1B). Thus, over two-thirds of LE patients classified at High

or Very High ASCVD event risk with out-of-range LDLc or non-HDLc values according to the

newly published guidelines were on no LDL-lowering medications.

Of the 82 LE patients classified at Extreme ASCVD event risk (secondary prevention),

only about one in ten achieved plasma concentrations of LDLc (8/82, 9.8%) or non-HDLc

(11/82, 13.4%) within the new goals. Nearly half were under-treated by the new guidelines,

meaning on LDL-lowering medications but still with out-of-range values for LDLc (37/82,

45.1%) or non-HDLc (34/82, 41.5%). About 30% were untreated, meaning out-of-range values

for LDLc (25/82, 30.5%) or non-HDLc (also 25/82, 30.5%) yet on no LDL-lowering

medications. The remainder of the LE patients classified at Extreme ASCVD event risk had no

LDLc (12/82, 14.6%) or HDLc (also 12/82, 14.6%) values available from their charts despite

documentation of clinically evident ASCVD, the key requirement for this risk category[1] (Figure

1B, Supplementary Figure S1B).

We used the ACC ASCVD Risk Estimator Plus to estimate the risk of an ASCVD event

in the next 10 years ("10-year ASCVD event risk") for all patients in the LE-ASCVD Study

Cohort meeting the criteria of no clinically evident ASCVD (n=288/370, 77.8% of the Study

Cohort; Figure 1A, Table 1), with sufficient available clinical data to allow use of this online risk

estimator (n=254), and ages 40-79 years (n=194). By performing age-scaling as described in the

Methods, we included an additional 47 patients below the age of 40 years (12.7% of the LE-

ASCVD Study Cohort) and 13 patients above 79 years (3.5% of the Study Cohort) without

clinically evident ASCVD and with sufficient data for this online ASCVD event risk estimator,

to analyze the entire subset of 254 patients just mentioned, i.e., nearly 90% of the LE-ASCVD

Study Cohort who had no clinically evident ASCVD (254/288, 88.2%).

Figure 1C displays data for these 254 patients stratified by estimates of their 10-year

ASCVD event risk from the ACC ASCVD Risk Estimator Plus, following the cutoffs of Arnett

et al. for primary prevention in the general population.[25] Of the patients with an estimated 10-

year ASCVD event risk of 7.5% to 19.9% from the ACC ASCVD Risk Estimator Plus, over half

were not on any LDL-lowering medication (n=43 out of 73, 58.9%; Figure 1C). Of patients with

an estimated 10-year ASCVD event risk ≥20%, 42.9% (n=12/28) were not on an LDL-lowering

medication recorded in the chart. Supplementary Figure S1C shows nearly identical results from

the original subset of 194 LE patients with no clinically evident ASCVD, sufficient data for this

online risk estimator, and aged 40-79 years with no age-scaling.

Of the LE patients who already have clinically evident ASCVD and are therefore

candidates for secondary prevention of ASCVD events, 41.5% (n=34/82) were not on any LDL-

lowering medication; this figure comprises Extreme Risk patients on no LDL-lowering

medication who have either (i) no LDLc value available (7 out of 12 from Figure 1A), (ii) the

most recent LDLc value within goal (2 out of 8 from Figure 1A), or (iii) the most recent LDLc

value above goal (25 from Figure 1B).

Figure 1D shows data for patients in the LE-ASCVD Study Cohort stratified by their

most recent plasma LDLc concentrations, and then within each LDLc concentration range, we

indicate treatment, or not, with an LDL-lowering medication. In each LDLc concentration

range, except for the lowest (<70 mg/dl) and the highest (≥190 mg/dl), over 60% of our LE

patients were on no LDL-lowering medications. There was no LDLc value available in the chart

for 45 patients (12.2% of the entire LE-ASCVD Study Cohort), nearly all of whom were on no

LDL-lowering medications (n=39/45, 86.7%). Supplementary Figure 1D shows data from

stratifying LE patients by their most recent plasma non-HDLc concentrations. Similar to our

findings with LDLc, in each concentration range of non-HDLc, except for the lowest (<80

mg/dl) and the highest (≥220 mg/dl), over 60% of LE patients were on no LDL-lowering

medications (Supplementary Figure S1D).

Assessments and management of hypertension

As noted above, almost three-quarters of the LE-ASCVD Study Cohort had hypertension

(266/370, 71.9%; Table 1). Of these 266 hypertensive lupus patients, approximately one-fourth

were well-managed, meaning normotensive on anti-hypertensive medications (68/266, 25.6%;

green in the leftmost column of Figure 2A); almost one half were under-treated, meaning on anti-

hypertensive medications but still hypertensive (122/266, 45.9%; green in the middle column of

Figure 2A); and almost one third were untreated, meaning hypertensive yet on no anti-

hypertensive medication (76/266, 28.6%; red in the middle column of Figure 2A). These data

indicate that hypertension is a common but undermanaged problem in lupus patients, consistent

with recently published literature using these blood pressure cut-offs.[17]

Smoking status and management

Figure 2B indicates the prevalence and management of tobacco smoking in the LE-

ASCVD Study Cohort. Of the former smokers in our cohort, the overwhelming majority quit

smoking without any documentation in the chart of smoking cessation counseling or referral to a

specialized smoking cessation clinic (n=92/109, 84.4%). Similarly, the overwhelming majority

of current smokers have no documentation in their charts of smoking cessation counseling or

clinic referral (n=51/63, 81.0%).

Assessments and management of HbA$_{1c}$ and plasma triglyceride levels

The majority (n=208/370, 56.2%) of patients in the LE-ASCVD Study Cohort had their

HbA$_{1c}$ levels checked at least once, with a median time elapsed time of 36 months (IQR 11-68)

since the last assay, i.e., three years (Supplementary Table S1). As with lipid/lipoprotein values,

PCPs checked just over 60% of the most recent HbA$_{1c}$ levels, and non-PCPs checked the rest. Of

the non-PCPs, rheumatologists checked HbA$_{1c}$ levels in more patients than did other

subspecialists (Supplementary Table S1).

Figure 2C shows assessment, or not, of HbA$_{1c}$ values in the LE-ASCVD Study Cohort

after stratification by obesity and/or current or previous glucocorticoid use, two common factors

in lupus patients that impair glycemic control. Of note, 51.0% (51 out of 100) of non-obese LE

patients on glucocorticoids, 30.6% (22/72) of obese LE patients not on glucocorticoids, and

38.6% (17/44) of obese LE patients on glucocorticoids had no HbA_{1c} value in their electronic

charts. In those three groups, 17.0% (n=17/100), 47.2% (n=34/72), and 31.8% (n=14/44) of the

patients had documented prediabetes or diabetes (blue and yellow in Figure 2C), suggesting that

obesity is a bigger driver of dysglycemia in the LE-ASCVD Study Cohort than are GCs. For

comparison, the figure for non-obese LE patients not on glucocorticoids is 23.4% (n=36/154;

leftmost column in Figure 2C). For patients whose most recent HbA_{1c} value was indicative of

prediabetes or diabetes, meaning ≥5.7%, the time elapsed since that abnormal value was 48

months (IQR 24-80), i.e., four years (Supplementary Table S1).

For LE patients with a diagnosis of prediabetes, almost half (33/67, 49.3%) did not have

documentation of lifestyle modification counseling or an active prescription for metformin

prescription in their charts (Figure 2D). For LE patients with diabetes, however, over three-

quarters were well-managed (n=30/39, 76.9%), and only 10.3% (4/39) had a most recent HbA_{1c}

>7% (Figure 2D).

Regarding triglyceride management, only 10.0% (10/100) of non-obese LE patients on

glucocorticoids, 5.6% (4/72) of obese LE patients not on glucocorticoids, and 9.1% (4/44) of

obese LE patients on glucocorticoids had no plasma triglyceride value in their electronic charts

(Figure 2E). Of all patients in the LE-ASCVD Study Cohort with available triglyceride values

(n=331 out of 370, 89.5%), only 0.6% (2/331) had very high levels (≥500 mg/dl) and only 6.0%

(20/331) had high levels (200-499 mg/dl; Figure 2E). These data indicate that

hypertriglyceridemia was not a common problem in our LE-ASCVD Study Cohort even amongst

patients with obesity and/or glucocorticoid therapy.

Comparisons of three different systems for estimating the risk of future ASCVD events in LE patients

We examined three systems for estimating the risk of future ASCVD events in LE patients – namely, the newly proposed risk categories of Keyes et al, which include both primary and secondary prevention,[1] and the two widely used online risk calculators, cited above, that estimate 10-year ASCVD event risk and are limited to primary prevention. To compare these systems in our LE-ASCVD Study Cohort, we focused on the subset of patients for whom both the QRisk3 and the ACC ASCVD Risk Estimator Plus could be used, meaning sufficient data in the electronic chart and no clinically evident ASCVD (n=254 out of 370 when including age scaling, i.e., the same number classified by the ACC ASCVD Risk Estimator Plus in Figure 1C). We separated these 254 patients into "High Risk" (n=41 out of 254; blue dots in Figure 3A,B) and "Very High Risk" (n=213/254; yellow dots in Figure 3A,C) following the categories of Keyes et al.[1] None of these 254 LE patients met criteria for the categories of "Extreme Risk" or "Recent Recurrent ASCVD Events" from Keyes et al., because both of those categories require clinically evident ASCVD, hence secondary prevention and ineligible for the QRisk3 or ACC ASCVD risk estimators.

Figure 3A shows estimates of each of these patient's 10-year ASCVD event risk from the QRisk3 and from the ACC calculator. Figure 3B shows both estimates of 10-year ASCVD event risk for only the LE patients who were stratified into the "High Risk" category of Keyes et al., with the axes expanded for ease of viewing the data. Figure 3C shows both 10-year ASCVD event risk estimates for only the LE patients stratified into the "Very High Risk" category of Keyes et al. Figure 3C allows an unobstructed view of the data for these Very High Risk

patients, indicating that many of them had remarkably low estimates of 10-year ASCVD event

risk from one or both of the online calculators, a point we return to in Figure 3D.

To directly compare the numerical estimates of 10-year ASCVD event risk from the

QRisk3 and the ACC ASCVD Risk Estimator Plus in our LE-ASCVD Study Cohort, we

performed Pearson's correlation with age scaling (Figure 3A, n=254 patients) and without age

scaling (Supplementary Figure S2A, n=194 patients, i.e., the same number classified by the ACC

ASCVD Risk Estimator Plus in Supplementary Figure S1C). Correlations were highly

statistically significant, with p-values of 1.78×10^{-41} and 1.40×10^{-27}, respectively. Nevertheless,

the r^2 values were surprisingly low, at 0.52 and 0.46, respectively. In other words, in our Study

Cohort, only about half of the variation in one widely used online 10-year ASCVD risk estimate

can be statistically attributed to variation in the other. Moreover, the y-intercepts were 6.9% and

7.7%, which are substantial compared with the cutoffs of Arnett et al.[25] and indicate generally

higher 10-year ASCVD risk estimates from the QRisk3 than from the ACC ASCVD Risk

Estimator Plus, particularly at the latter's lower end. Visual inspection of Figure 3A-C and

Supplementary Figure S2A demonstrates this point as well.

Figure 3D indicates clinically meaningful agreement (green) and discordance (red, white)

amongst the three systems for estimating the risk of a future ASCVD event for individual

patients in the LE-ASCVD Study Cohort. As described in the Methods, we compared the two

online calculators with the newly proposed categories of ASCVD event risk for LE patients from

Keyes et al. by using the key cutoff of 7.5% estimated 10-year ASCVD event risk from Arnett et

al.'s guidelines for the general population, because estimates ≥7.5% come with substantially

more aggressive recommendations for management compared with recommendations for

estimates <7.5%.[25] In Figure 3D, green indicates clinically meaningful agreement, defined here

as classification of an LE patient into the "High Risk" or "Very High Risk" categories of Keyes

et al., with estimates of 10-year ASCVD event risk ≥7.5% from both of the online calculators.

Red indicates clinically significant discordance between the two online calculators, meaning one

estimate of 10-year ASCVD event risk <7.5% but the other ≥7.5% for the same LE patient.

White indicates discordance between Keyes et al. versus both of the online risk estimators, i.e.,

these patients are at High or Very High Risk according to Keyes et al., yet both online

calculators gave estimates of 10-year ASCVD event risk <7.5%. By these definitions of

clinically meaningful agreement and discordance, the three systems for estimating the risk of a

future ASCVD event were in agreement for only 100 of the 254 LE patients (39.4%), i.e.,

discordance for almost two-thirds of the LE patients (154/254, 60.6%) that could affect their

clinical management. Supplementary Figure S2B shows similar findings for the 194 LE patients

without age scaling.

Clinically documented ASCVD Events and actual 10-year ASCVD event rate in the LE-ASCVD

Study Cohort

Because of discordances amongst the three systems for estimating ASCVD event *risk*

(Figure 3), we sought to determine the actual 10-year ASCVD event *rate* in our LE-ASCVD

Study Cohort. Figure 4 shows the Kaplan-Meier curve of event-free survival, with 95%

confidence intervals, since enrollment. For completeness, Supplementary Figure S3 shows the

cumulative incidence of all documented MAACE in our LE-ASCVD Study Cohort, including

the period before enrollment (indicated at time 0) and then all first MAACE after enrollment

(time >0). Table 2 gives a breakdown of the types of MAACE.

The rate of ASCVD events for patients in the first 10 years after enrollment into our LE-

ASCVD Study Cohort was calculated as one minus the event-free survival at the 10-year time

point of the Kaplan-Meier survival curve (Figure 4). Thus, the 10-year ASCVD event rate was

22.3% (95% CI 16.9%, 27.4%), which is above Arnett et al.'s highest cut-off of 20%,[25]

indicating a high-risk population.

This 10-year ASCVD event rate in our LE-ASCVD Study Cohort is even more striking,

given the preponderance of women and the patients' relative youth at enrollment (Table 1). For

comparison, the ACC ASCVD Risk Estimator Plus gives an estimate of 10-year ASCVD event

risk ≥20% for a 47-year-old woman if she has a combination of diabetes, current smoking,

treated hypertension, an HDLc of 40 mg/dl, and a non-HDLc ≥250 mg/dl if Caucasian and ≥160

mg/dl if African-American.

Discussion

Our results indicate that CLE patients are under-treated compared with the new guidelines for conventional therapeutic targets to prevent ASCVD events[1] and, accordingly, these patients experience a substantial burden of major adverse ASCVD events despite our youngish, predominantly female LE-ASCVD Study Cohort. Moreover, current methods give discordant estimates of the risk for future ASCVD events, possibly because the online risk calculators were not designed specifically for CLE patients. Thus, for patients with cutaneous LE, it is unclear how to accurately assess their future ASCVD event risk – except that it is high – and this uncertainty may complicate clinical management. Management of ASCVD event risk has become a major issue in LE because of therapeutic success: lupus patients are now much less likely to die prematurely from lupus directly or from infections, and so they are living long enough to develop clinically significant atherosclerotic cardiovascular disease.[1, 6]

Specific areas of current concern include under-management of LDLc, non-HDLc, and presumably apoB levels to the new guidelines;[1] under- or non-administration of LDL-lowering therapies in primary and even secondary prevention; management of hypertension to recently revised blood-pressure goals;[17, 33] under-use of resources for smoking cessation; infrequent monitoring of above-goal LDLc and HbA_{1c} levels; under-management of prediabetes; and, as noted above, clinically meaningful discordances in estimates of the risk for future ASCVD events and a strikingly high 10-year ASCVD event rate. Areas of current success include high levels of linkage with a PCP; evidence of widespread awareness amongst PCPs and sub-specialists of conventional therapeutic targets for management of ASCVD event risk; generally well-managed diabetes mellitus; and low prevalence of hypertriglyceridemia in the LE-ASCVD Study Cohort even in patients with obesity and/or GC use.

Our findings add to a growing literature emphasizing the gaps between typical or usual

real-world care versus ideal guideline-based care in the management of ASCVD event risk in

lupus patients and in non-autoimmune populations, even ones at high risk. Several studies have

looked at rates of cardiovascular events in CLE cohorts.[1, 11] To our knowledge, however, ours is

the first study to focus on the management of ASCVD event risk in CLE, although there is prior

literature in SLE.[1] In one published study, a large proportion of a cohort of 110 patients with

SLE had indications for statins for primary or secondary prevention, but only about half of those

were treated to guidelines.[16] In a recently reported cohort of 1532 SLE patients,[17] 639 had

hypertension defined by the new cutoffs of $\geq$130/$\geq$80 mm Hg or on anti-hypertensive

medications, but approximately three-quarters of these hypertensive SLE patients (471/639,

73.7%) were under- or un-treated, nearly identical to our figure of 74.4% (198/266, Figure 2A).

Moreover, lupus patients with blood pressures in the newly defined range for stage 1

hypertension, meaning 130–139/80–89 mm Hg,[33] had more than twice the rate of atherosclerotic

cardiovascular events than did normotensive lupus patients during a decade or so of follow-up.[17,

43] In other SLE cohorts as well, persistent hypertension has been associated with a much higher

incidence of ASCVD events, compared with ASCVD event rates in normotensive SLE

patients.[44]

In non-autoimmune populations, treatment of therapeutic targets to manage ASCVD

event risk, particularly hypercholesterolemia[45-49] and hypertension,[50, 51] remains sub-optimal in

the USA and worldwide. Particularly striking are under-utilization of evidence-based LDL- and

blood pressure-lowering medications in patients with diabetes mellitus,[52, 53] even when those

patients are at extreme ASCVD event risk owing to the additional presence of clinically evident

atherosclerosis (secondary prevention) on top of their type 2 diabetes.[48]

Reasons for this widespread pattern of undertreatment might stem from prioritization of

immediate clinical problems over long-term care, difficulties for patients and providers in

sustaining long-term treatment for subclinical conditions, time needed to disseminate and

implement recent guidelines, access to care, the difficulties of polypharmacy, evidence-based

and non-evidence-based concerns from patients and providers over potential side-effects,[49, 54]

and lifestyle and medication adherence. Further research is needed so that rational strategies can

be developed to address under-management of ASCVD event risk. Amongst conventional

therapeutic targets in the management of ASCVD event risk, levels of LDLc, non-HDLc, and

apoB can be managed without great concern of a lower limit,[55, 56] in contrast to blood pressure or

plasma glucose levels. Conventional interventions to assist smoking cessation and to manage

prediabetes also come with few risks.

Notably, our results emphasize the need to clarify how to appropriately assess the risk of

future ASCVD events in CLE patients. We demonstrated discordance amongst the three systems

that we used: the new risk classifications from Keyes et al. specifically for lupus patients,[1] the

ACC ASCVD Risk Estimator Plus,[24, 25] and the QRisk3 calculator.[26-28] A similar discordance

between the Framingham Risk Score and QRisk3 was recently reported for SLE patients in one

study[57] but less so in another study with a far smaller cohort.[16] As a statistical matter,

multiplying the 10-year estimate from the ACC Risk Estimator Plus by 1.5, as has been

proposed,[1, 39] would not improve the r^2 value of the correlation with QRisk3. Recent reports

suggest that QRisk3 may be a better predictor for lupus patients than other estimators of future

ASCVD event risk.[58, 59] Additional clinical parameters that may enhance assessment of ASCVD

event risk in lupus patients may include plasma apoB measurements,[1, 60] one-time assessments

of plasma lipoprotein(a) levels, which are still largely genetically determined[1], and arterial

imaging to detect subclinical plaque by femoral or carotid ultrasonography, coronary CT

angiography, and in older patients coronary artery calcium scores.[1]

Study Limitations and Strengths

Study limitations include the retrospective design, from a single medical center. In our

database, like many others, there are possible inaccuracies in smoking status because assays of

cotinine, a recognized marker of nicotine use, are not part of routine care. Lifestyle modifications

or medications discussed at a clinic visit but not entered into the charts could indicate a different

level of management. In addition, the standard of care for diabetes testing includes assays in

addition to HbA_{1c}, such as fasting glucose levels, oral glucose tolerance tests (OGTT), and

random plasma glucose levels, which may also be used to diagnose and assess prediabetes and

diabetes.[34] As noted in Figure 2C, many patients in our LE-ASCVD Study Cohort had no

available HbA_{1c} values, which affects our statistics on prevalence of prediabetes and diabetes and

their management.

Study strengths include a well-characterized longitudinal Cohort followed for over 14

years, with key parameters available in the electronic charts. The study assessed all available

conventional therapeutic targets in managing ASCVD event risk, which has not been previously

done in a comprehensive manner in CLE patients. Moreover, our results identified specific, key

issues in clinical management and decision-making. Based on our findings, efforts are now

underway to improve ASCVD event risk estimation and guideline implementation in lupus

patients.

552
553
554
555

Contributions: MZ, VPW, and KJW, were involved in the conceptualizing the project, writing the
manuscript, and editing the manuscript. MZ was responsible for data collection, and MZ and
KJW were responsible for data verification. MZ, RF, and KJW were responsible for data
analysis.

Funding: Support by the Lupus Foundation of America was given for this study as part of the
2021 Gina M. Finzi Student Fellowship (to MZ). The work was also supported by the National
Institutes of Health-USA (NIH-USA) grants K24-AR02207 and R01AR071653 (to VPW), the
United States Department of Veterans Affairs (Veterans Health Administration, Office of
Research and Development and Biomedical Laboratory Research and Development, to VPW),
and the Ruth and Yonatan Ben-Avraham Fund (to KJW).

Competing interests: All authors declare no support from any organization for the submitted
work; no financial relationships with any organizations that might have an interest in the
submitted work in the previous three years; no other relationships or activities that could appear
to have influenced the submitted work. KJW discloses an ownership interest in Hygieia, Inc., a
company that provides insulin management services.

Data sharing: De-identified patient-level data, the full dataset, and statistical code are available
from the first author (MZ, megan.zhao@pennmedicine.upenn.edu). Participant consent for data
sharing was not obtained but the presented data are anonymized and risk of identification is low.

Ethics: This study was approved by the University of Pennsylvania Institutional Review Board;
IRB PROTOCOL#: 849182

Transparency Declaration: This manuscript is an honest, accurate, and transparent account of
the study being reported. There are no important aspects of the study have been omitted and
discrepancies have been explained. There are no competing interests.

References
1. Keyes, E., et al., *Assessment and management of the heightened risk for atherosclerotic*
cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J
Womens Dermatol, 2021. **7**(5Part A): 560-575.
2. Akarsu, S., et al., *High prevalence of metabolic syndrome in patients with discoid lupus*
erythematosus: a cross-sectional, case-control study. J Immunol Res, 2017. **2017**:
3972706.
3. Miot, H.A., L.D. Bartoli Miot, and G.R. Haddad, *Association between discoid lupus*
erythematosus and cigarette smoking. Dermatology, 2005. **211**(2): 118-22.
4. Bockle, B.C. and N.T. Sepp, *Smoking is highly associated with discoid lupus*
erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus, 2015.
24(7): 669-74.
5. Guo, L.N. and V.E. Nambudiri, *Cutaneous lupus erythematosus and cardiovascular*
disease: current knowledge and insights into pathogenesis. Clin Rheumatol, 2021. **40**(2):
491-499.

6.   Urowitz, M.B., et al., *The bimodal mortality pattern of systemic lupus erythematosus*. Am
J Med, 1976. **60**(2): 221-5.
7.   Roman, M.J., et al., *Prevalence and correlates of accelerated atherosclerosis in systemic
lupus erythematosus*. N Engl J Med, 2003. **349**(25): 2399-406.
8.   Asanuma, Y., et al., *Premature coronary-artery atherosclerosis in systemic lupus
erythematosus*. N Engl J Med, 2003. **349**(25): 2407-15.
9.   Carlucci, P.M., et al., *Neutrophil subsets and their gene signature associate with vascular
inflammation and coronary atherosclerosis in lupus*. JCI Insight, 2018. **3**(8).
10.   Salmon, J.E. and M.J. Roman, *Subclinical atherosclerosis in rheumatoid arthritis and
systemic lupus erythematosus*. Am J Med, 2008. **121**(10 Suppl 1): S3-8.
11.   Shams-Eldin, A.N., et al., *Long-term risk of adverse cardiovascular outcomes associated
with cutaneous lupus erythematosus: a nationwide cohort study*. Clin Rheumatol, 2022.
41(11): 3525-3536.
12.   Williams, K.J. and I. Tabas, *The response-to-retention hypothesis of early atherogenesis*.
Arterioscler Thromb Vasc Biol, 1995. **15**(5): 551-61.
13.   Borén, J. and K.J. Williams, *The central role of arterial retention of cholesterol-rich
apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a
triumph of simplicity*. Curr Opin Lipidol, 2016. **27**(5): 473-83.
14.   Elliott, J.R., S. Manzi, and D. Edmundowicz, *The role of preventive cardiology in
systemic lupus erythematosus*. Curr Rheumatol Rep, 2007. **9**(2): 125-30.
15.   Munguia-Realpozo, P., et al., *Systemic lupus erythematosus and hypertension*.
Autoimmun Rev, 2019. **18**(10): 102371.
16.   Masson, W., et al., *Cardiovascular risk stratification and appropriate use of statins in
patients with systemic lupus erythematosus according to different strategies*. Clin
Rheumatol, 2020. **39**(2): 455-462.
17.   Tselios, K., et al., *Impact of the new American College of Cardiology/American Heart
Association definition of hypertension on atherosclerotic vascular events in systemic
lupus erythematosus*. Ann Rheum Dis, 2020. **79**(5): 612-617.
18.   Moghadam-Kia, S., et al., *Cross-sectional analysis of a collaborative Web-based
database for lupus erythematosus-associated skin lesions: prospective enrollment of 114
patients*. Arch Dermatol, 2009. **145**(3): 255-60.
19.   Chang, A.Y., et al., *Response to antimalarial agents in cutaneous lupus erythematosus: a
prospective analysis*. Arch Dermatol, 2011. **147**(11): 1261-7.
20.   Piette, E.W., et al., *Impact of smoking in cutaneous lupus erythematosus*. Arch Dermatol,
2012. **148**(3): 317-22.
21.   Wieczorek, I.T., et al., *Systemic symptoms in the progression of cutaneous to systemic
lupus erythematosus*. JAMA Dermatol, 2014. **150**(3): 291-6.
22.   Keyes, E., et al., *Comparative responsiveness of cutaneous lupus erythematosus patients
to methotrexate and mycophenolate mofetil: A cohort study*. J Am Acad Dermatol, 2021.
98(2): 447-448.
23.   Zeidi, M., et al., *Increased CD69+CCR7+ circulating activated T cells and STAT3
expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials*.
Lupus, 2022. **31**(4): 472-481.
24.   *American College of Cardiology. https://tools.acc.org/ASCVD-Risk-Estimator-
Plus/#!/calculate/estimate/*

639	25.	Arnett, D.K., et al., *2019 ACC/AHA Guideline on the Primary Prevention of*
640		*Cardiovascular Disease: A Report of the American College of Cardiology/American*
641		*Heart Association Task Force on Clinical Practice Guidelines*. Circulation, 2019.
642		**140**(11): e596-e646.
643	26.	Hippisley-Cox, J., C. Coupland, and P. Brindle, *Development and validation of QRISK3*
644		*risk prediction algorithms to estimate future risk of cardiovascular disease: prospective*
645		*cohort study*. BMJ, 2017. **357**: j2099.
646	27.	Edwards, N., et al., *QRISK3 improves detection of cardiovascular disease risk in patients*
647		*with systemic lupus erythematosus*. Lupus Sci Med, 2018. **5**(1): e000272.
648	28.	QRISK3. https://qrisk.org/three/
649	29.	The Global BMI Mortality Collaboration, *Body-mass index and all-cause mortality:*
650		*individual-participant-data meta-analysis of 239 prospective studies in four continents*.
651		Lancet, 2016. **388**(10046): 776-86.
652	30.	Sniderman, A.D., *How, when, and why to use apolipoprotein B in clinical practice*. Am J
653		Cardiol, 2002. **90**(8A): 48i-54i.
654	31.	Wu, M.F., et al., *Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current*
655		*Understanding and Future Perspectives*. Cardiovasc Drugs Ther, 2019. **33**(6): 739-748.
656	32.	Page, M.M. and G.F. Watts, *Contemporary perspectives on the genetics and clinical use*
657		*of lipoprotein(a) in preventive cardiology*. Curr Opin Cardiol, 2021. **36**(3): 272-280.
658	33.	Whelton, P.K., et al., *2017*
659		*ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the*
660		*Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A*
661		*Report of the American College of Cardiology/American Heart Association Task Force*
662		*on Clinical Practice Guidelines*. Hypertension, 2018. **71**(6): e13-e115.
663	34.	American Diabetes Association, *2. Classification and Diagnosis of Diabetes: Standards*
664		*of Medical Care in Diabetes-2021*. Diabetes Care, 2021. **44**(Suppl 1): S15-S33.
665	35.	Knowler, W.C., et al., *Reduction in the incidence of type 2 diabetes with lifestyle*
666		*intervention or metformin*. N Engl J Med, 2002. **346**(6): 393-403.
667	36.	Nathan, D.M. et al, *The diabetes control and complications trial/epidemiology of*
668		*diabetes interventions and complications study at 30 years: overview*. Diabetes Care,
669		2014. **37**(1): 9-16.
670	37.	Diabetes Prevention Program Research Group, *Long-term Effects of Metformin on*
671		*Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes*
672		*Prevention Program and Diabetes Prevention Program Outcomes Study*. Diabetes Care,
673		2019. **42**(4): 601-608.
674	38.	Goldberg, R.B., et al., *Effects of Long-term Metformin and Lifestyle Interventions on*
675		*Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study*.
676		Circulation, 2022. **145**(22): 1632-1641.
677	39.	Urowitz, M.B., et al., *Modified Framingham Risk Factor Score for Systemic Lupus*
678		*Erythematosus*. J Rheumatol, 2016. **43**(5): 875-9.
679	40.	Kaplan, E.L., and P. Meier, *Nonparametric estimation from incomplete observations*. J
680		Am Stat Assoc, 1958. **53.282**: 457-481.
681	41.	Rich, J.T., et al., *A practical guide to understanding Kaplan-Meier curves*. Otolaryngol
682		Head Neck Surg, 2010. **143**(3): 331-6.

42. Hesselvig, J.H., et al., *Increased risk of depression in patients with cutaneous lupus
erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study*. Br J
Dermatol, 2018. **179**(5): 1095-1101.
43. Ming Wang, T.K., et al., *Cardiovascular manifestations, imaging, and outcomes in
systemic lupus erythematosus: an eight-year single center experience in the United
States*. Angiology, 2022. **73**(9): 877-886.
44. Kiani, A.N., et al., *Predictors of progression in atherosclerosis over 2 years in systemic
lupus erythematosus*. Rheumatology (Oxford), 2011. **50**(11): 2071-9.
45. Kuklina, E.V., P.W. Yoon, and N.L. Keenan, *Trends in high levels of low-density
lipoprotein cholesterol in the United States, 1999-2006*. JAMA, 2009. **302**(19): 2104-10.
46. Carroll, M.D., et al., *Total and high-density lipoprotein cholesterol in adults: National
Health and Nutrition Examination Survey, 2011-2012*. NCHS Data Brief, 2013(132): 1-8.
47. Mercado, C., et al., *Prevalence of cholesterol treatment eligibility and medication use
among adults--United States, 2005-2012*. MMWR Morb Mortal Wkly Rep, 2015. **64**(47):
1305-11.
48. Nelson, A.J., et al., *Use of lipid-, blood pressure-, and glucose-lowering
pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular
disease*. JAMA Netw Open, 2022. **5**(2): e2148030.
49. Stone, N.J., *Treating Severe Hypercholesterolemia-If Not Now, When?* JAMA Cardiol,
2022. **7**(2): 128-129.
50. Yoon, S.S., et al., *Trends in blood pressure among adults with hypertension: United
States, 2003 to 2012*. Hypertension, 2015. **65**(1): 54-61.
51. Ciemins, E.L., et al., *Application of a Tool to Identify Undiagnosed Hypertension -
United States, 2016*. MMWR Morb Mortal Wkly Rep, 2018. **67**(29): 798-802.
52. Kazemian, P., et al., *Evaluation of the Cascade of Diabetes Care in the United States,
2005-2016*. JAMA Intern Med, 2019. **179**(10): 1376-1385.
53. Fang, M., et al., *Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018*. N
Engl J Med, 2021. **384**(23): 2219-2228.
54. Wood, F.A., et al., *N-of-1 Trial of a statin, placebo, or no treatment to assess side effects*.
N Engl J Med, 2020. **383**(22): 2182-2184.
55. Mach, F., et al., *2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid
modification to reduce cardiovascular risk*. Eur Heart J, 2020. **41**(1): 111-188.
56. Ference, B.A., *Interpreting the clinical implications of drug-target Mendelian
randomization studies*. J Am Coll Cardiol, 2022. **80**(7): 663-665.
57. Sivakumaran, J., et al., *Assessment of cardiovascular risk tools as predictors of
cardiovascular disease events in systemic lupus erythematosus*. Lupus Sci Med, 2021.
8(1).
58. Zhu, L., et al., *Assessing the validity of QRISK3 in predicting cardiovascular events in
systemic lupus erythematosus*. Lupus Sci Med, 2022. **9**(1).
59. Quevedo-Abeledo, J.C., et al., *QRISK3 relation to carotid plaque is higer than that of
score in patients with systemic lupus erythematosus*. Rheumatology (Oxford), 2022.
61(4): 1408-1416.
60. Sniderman, A.D., et al., *Apolipoprotein B particles and cardiovascular disease: a
narrative review*. JAMA Cardiol, 2019. **4**(12): 1287-1295.
727
728

Table 1. Demographics and other characteristics of the LE-ASCVD Study Cohort. Here and elsewhere, categorical parameters are given as n (%). Continuous variables are given as mean±SD, if normally distributed, or as median (interquartile range, IQR), if non-normally distributed.

Category	Parameter	Value	n in LE-ASCVD Study Cohort or subgroup
Demographics			
	Female	305 (82.4%)	370 (entire LE-ASCVD Study Cohort)
	White	190 (51.4%)	370
	Black	141 (38.1%)	370
	Asian	15 (4.1%)	370
	Hispanic	17 (4.6%)	370
Clinical course and care in the Cohort			
	Age at enrollment into the Cohort	47.1±14.9 years	370
	Age as of 2021	54.8±15.9 years	370
	Length of time since enrollment into the Cohort	7.7±4.5 years	370
	Extreme Risk for future ASCVD events*	82 (22.2%)	370
	CLE patients with concurrent SLE	190 (51.4%)	370
	History of lupus nephritis	42 (11.4%)	370
	History of CKD stage 3 or 4‡	37 (10.0%)	370
	Hypertension§	266 (71.9%)	370
	Former Smokers	109 (29.5%)	370
	Current Smokers	63 (17.0%)	370
	Most recent BMI	28.4±7.1 kg/m^2	346 (subgroup with at least one set of simultaneous height and weight measurements)
	Obese (BMI ≥30.0 kg/m^2)	116 (33.5%)	346
	Prediabetes	67 (18.1%)	370

	Diabetes mellitus	39 (10.5%)	370
Provider Data			
	Patients with a listed PCP in the chart	336 (90.8%)	370
	Patients with documented PCP visit in the chart	279 (75.4%)	370

BMI, body mass index; PCP, primary care provider.

*Extreme ASCVD event risk was defined by Keyes et al. 2021 as "Patients with LE … and

clinically evident ASCVD", i.e., secondary prevention in the context of LE.[1]

‡An additional five (1.4%) patients in the LE-ASCVD Study Cohort were in CKD stage 5,

meaning an eGFR below 15 ml/min/1.73m^2.

§Hypertension was defined following Whelton et al. 2018 as a systolic BP ≥130 mm Hg, a

diastolic BP ≥80 mm Hg, and/or on an anti-hypertensive medication,[33] here based on averaged

blood pressure readings from the most recent year of follow-up, plus the list of active

prescriptions in the electronic charts. 341 patients (92.3% of the LE-ASCVD Cohort) had two or

more readings in their electronic charts in this period; 28 patients (7.6%) had only one reading;

and 1 patient had no available blood pressure value in the most recent year.

750   **Table 2.** Types, numbers, and timing of major adverse atherosclerotic cardiovascular events

751   (MAACE) documented in the LE-ASCVD Study Cohort.

Type of MAACE	Number affected (% of the 370 patients in the LE-ASCVD Study Cohort)*	Time from enrollment to event in years, given as median (IQR); and number of events (n)‡
Atherosclerotic myocardial infarction (MI)	14 (3.8%)	6.5 (4-11); n=12
Newly diagnosed ischemic heart disease other than MI	31 (8.4%)	8.0 (5-13); n=25
Atherosclerotic (non-embolic) ischemic stroke or transient cerebrovascular ischemic attack	15 (4.1%)	11.0 (7-14); n=10
Newly diagnosed symptomatic peripheral vascular disease (PVD)	3 (0.8%)	5.0; n=3
Hospitalization for chest pain, shortness of breath, or palpitations with suspicion of ischemic origin	29 (7.8%)	7.0 (5-8); n=28
Any MAACE	82 (22.2%)	7.0 (5-11); n=65

*Any patient who experienced two or more MAACE before and since enrollment was counted

only once in any given row but was counted in two or more rows if the types of MAACE

differed. Thus, the sum of the numbers of patients affected by each specific type of MAACE (92

total, 78 since enrollment) is slightly larger than the number of patients affected by any MAACE

(82 total, 65 since enrollment).

‡Time and n in this column exclude the 17 events that were documented in lupus patients before

their enrollment in the LE-ASCVD Study Cohort. IQR ranges are given for each type of

MAACE only if n ≥6.

Figure 1. Assessment and management of plasma low-density lipoprotein cholesterol (LDLc) concentrations in the LE-ASCVD Study Cohort. <u>Panel A</u>: Classification of Study Cohort patients into the four categories of ASCVD event risk defined by the newly proposed guidelines of Keyes et al. for lupus patients.[1] Also indicated are numbers of patients with LDLc levels above (red) or within (green) the newly proposed goals for each risk category. Patients without an available LDLc value are indicated in blue. <u>Panel B</u>: Absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic charts of patients classified into each of the four newly proposed categories of ASCVD event risk for lupus patients and whose most recent plasma LDLc levels were above the newly proposed goals; these are the patients indicated in red in panel 1A. <u>Panel C</u>: Estimated risk of an ASCVD event in the next 10 years ("10-year ASCVD event risk") by the online ACC Risk Estimator Plus and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. Patients are grouped according to the cut-offs for estimated 10-year ASCVD event risk from the ACC/AHA Guideline on primary prevention (0.0-4.9%, 5.0-7.4%, &c.).[25] As noted in the Methods, patients below age 40 years without clinically evident ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus (n=47/370) were scaled up to 40, and patients above age 79 years without clinically evident ASCVD (n=13/370) were scaled down to 79. Data are presented with these additional patients included (here) or presented separately in their own columns (Supplementary Figure S1C). Also shown here are data for patients with clinically evident ASCVD (meaning secondary prevention, for which the ACC ASCVD Risk Estimator Plus does not apply), as well as data for patients with no clinically evident ASCVD but insufficient information in the electronic chart for the ACC Risk Estimator (rightmost column). <u>Panel D</u>: Most recent LDLc values and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. The rightmost column represents patients with no LDLc value in the electronic chart. At the top of each column in panels A-D is indicated the total number of patients represented by that column. Numbers of patients represented by each tinted portion of each column are also given.

808
809
810

823
824
825

826
827
828

Figure 2. Assessment and management of several exacerbators and an additional causative agent
of ASCVD event risk in the LE-ASCVD Study Cohort. Panel A: Prevalence and management of
hypertension. Under-treated or untreated hypertension is defined by a blood pressure (BP)
$\geq$130/80 mm Hg, meaning a systolic BP $\geq$130 and/or a diastolic BP $\geq$80. Red indicates patients
with no record of an active prescription for an anti-hypertensive medication in the electronic
chart; green indicates patients on at least one anti-hypertensive medication. Panel B: Prevalence
and management of tobacco smoking. Red indicates patients with no chart documentation of
either smoking cessation counseling or a referral to a smoking cessation clinic; green indicates
patients with a record of one or both of these interventions. Data from never-smokers are also
shown (blue). Panel C: Assessment, or not (red), of glycated hemoglobin (HbA_{1c}) values for
patients stratified by obesity and/or glucocorticoid (GC) use, two common factors in lupus
patients that impair glycemic control. Diabetes is defined as chart-diagnosed or the most recent
HbA_{1c} was $\geq$6.5%; yellow indicates diabetes and at least one HbA_{1c} value on the chart. Five
patients had a diagnosis of diabetes on their charts but no available HbA_{1c} value; these patients
are included within the red portions of the columns here. Prediabetes (blue) is defined as chart-
diagnosed or the most recent HbA_{1c} was 5.7-6.4%, without a diagnosis of overt diabetes on the
chart. Green indicates patients with at least one HbA_{1c} value on the chart and no indication of
either prediabetes or diabetes. Panel D: Management of prediabetes and diabetes in the LE-
ASCVD Study Cohort. For prediabetes, well-managed (green) is defined here as documentation
in the chart of lifestyle counseling and/or an active prescription for metformin. For diabetes,
well-managed (green) is defined here as the most recent $HbA_{1c} \leq$7%. Red indicates not well-
managed by these definitions. Yellow in this panel indicates a diagnosis of diabetes but no
available HbA_{1c} value on the chart. Panel E: Assessment, or not (red), of plasma triglyceride
(TG) concentrations for patients stratified by obesity and/or GC use, two common factors in
lupus patients that can elevate plasma TGs. Most recent plasma TG values are classified as very
high ($\geq$500 mg/dl, yellow), high (200-499 mg/dl, blue), or <200 mg/dl (green).
855

856
857

858
859

Figure 3. Three systems to estimate the risk of a future ASCVD event for individual patients within the LE-ASCVD Study Cohort. The three system were the ASCVD event risk categories defined by Keyes et al. for LE patients (reference[1] and Fig 1A); and numerical estimates of the risk of an ASCVD event in the next 10 years ("10-year ASCVD event risk") generated by two widely used online calculators: QRisk3 (y-axis) versus the American College of Cardiology (ACC) ASCVD Risk Estimator Plus (x-axis). Data are shown for the subset of patients in the Study Cohort for whom both online calculators could be used, meaning no clinically evident ASCVD (primary prevention) and sufficient data in the electronic charts to allow use of these online tools. Data are presented with (here, n=254) and without (Supplementary Figure S2, n=194) age scaling for the ASCVD Risk Estimator Plus. Each dot represents an individual patient. Blue dots indicate patients classified at "High Risk" (n=41/254), and yellow dots indicate patients classified at "Very High Risk" (n=213/254) according to Keyes et al. The horizontal and vertical dashed gray lines indicate the key cut-off of 7.5% estimated 10-year ASCVD event risk from Arnett et al. 2019,[25] for each of the two calculators. P-values were calculated with linear regression. Panel A: Three estimates of ASCVD event risk for each of the 254 eligible LE patients. Pearson's linear correlation was used to test the statistical relationship between the two numerical estimates of 10-year ASCVD event risk, and the calculated regression line is indicated in dashed red with key parameters given on the right. Panel B: Estimates of 10-year ASCVD event risk for LE patients classified into the "High Risk" category of Keyes et al. The panel has been expanded for ease of viewing the data. Panel C: Estimates of 10-year ASCVD event risk for LE patients classified into the "Very High Risk" category of Keyes et al. The panel allows an unobstructed view of the data for these Very High Risk patients. Panel D: Clinically meaningful agreement (green) and discordance (red, white) amongst the three systems for estimating the risk of a future ASCVD event for individual patients in the LE-ASCVD Study Cohort. The two pie charts tabulate patients from Fig. 3B ("High Risk" as defined by Keyes et al., n=41) and Fig. 3C ("Very High Risk" as defined by Keyes et al., n=213). Green indicates clinically meaningful agreement, defined here as classification of an LE patient into the "High Risk" or "Very High Risk" categories of Keyes et al., with estimates of 10-year ASCVD event risk ≥7.5% from both of the online calculators. Red indicates clinically significant discordance between the two online calculators, meaning one estimate of 10-year ASCVD event risk <7.5% but the other ≥7.5% for the same LE patient. White indicates discordance between Keyes et al. versus both of the online risk estimators, i.e., these patients are at High or Very High Risk according to Keyes et al., yet both online calculators gave estimates of 10-year ASCVD event risk <7.5%. Numbers of patients represented by each portion of each pie chart are also given.

913
914

B

943
944
945
946

947
948
949
950

952
953

Figure 4. Kaplan-Meier curve of event-free survival since enrollment in the LE-ASCVD Study
Cohort. An event was defined as a patient's first documented major adverse atherosclerotic
cardiovascular event (MAACE) after enrollment. Displayed are median event-free survival rates
over time (solid black stepped curve) with 95% confidence intervals (dashed curves). Following
our definition, the 17 MAACE that were documented before enrollment are not shown on this
graph. All patients in the LE-ASCVD Study Cohort were included in this survival curve. The
actual documented 10-year ASCVD event rate in this Cohort was calculated as one minus the
event-free survival rate of 0.777 (95% CI 0.726, 0.831) at the 10-year time point, which is
highlighted by the thin vertical gray line.
963

 Supplementary Table and Figures

977 **Supplementary Table S1.** Additional characteristics of the LE-ASCVD Study Cohort.

978 Categorical parameters are given as n (%). Continuous variables are given as mean±SD, if

979 normally distributed, or as median (interquartile range, IQR), if non-normally distributed.

Category	Parameter	Value	n in LE-ASCVD Study Cohort or subgroup
Additional clinical characteristics			
	Time since diagnosis of cutaneous LE	13.0 years (IQR 8.25-21.0)	370 (entire LE-ASCVD Study Cohort)
	Time since diagnosis of cutaneous LE	15.0 years (IQR 10.0-25.0)	190 (subgroup of CLE patients who have concurrent SLE)
	Time since diagnosis of systemic LE	13.0 years (IQR 8.00-23.8)	190 (same subgroup as above)
	Underweight (BMI <18.5 kg/m^2, common definition)	13 (3.8%)	346 (subgroup with at least one set of simultaneous height and weight measurements)
	Underweight (BMI <20.0 kg/m^2 [29])	21 (6.1%%)	346
	Normal weight (BMI 18.5 to 24.9 kg/m^2, common definition)	112 (32.4%)	346
	Normal weight (BMI 20.0-24.9 kg/m^2 [29])	104 (30.1%)	346
	Overweight (BMI 25.0 to 29.9 kg/m^2)	105 (30.3%)	346
	Diagnosis of depression in the electronic chart	139 (37.6%)	370
Additional data regarding providers			
	Time since last visit with PCP	10 months (IQR 4.0-31)	279 (subgroup with at least one PCP visit documented in the chart)

	Number of physician providers, excluding trainees	5.8±2.8 (mean±SD)	370
	Patients who have a recorded visit with a rheumatologist	203 (54.9%)	370
	Patients who have a recorded visit with a cardiologist	151 (40.8%)	370
	Patients who have a recorded visit with a nephrologist	57 (15.4%)	370
	Patients who have a recorded visit with an endocrinologist	33 (8.0%)	370
Assessments of plasma lipids/lipoproteins			
	Lipids/lipoproteins checked at least once	325 (87.8%)	370
	Time since the most recently documented lipid/lipoprotein assay	35 months (IQR 14-83)	325 (subgroup with at least one lipid/lipoprotein result in the chart)
	PCP checked the most recent lipids/lipoproteins	204 (62.8%)	325
	Non-PCPs checked the most recent lipids/lipoproteins	121 (37.2%)	325
	• Rheumatology	35 (28.9%)	121 (subgroup for whom non-PCPs checked the most recent lipids/lipoproteins)
	• Cardiology	15 (12.4%)	121
	• Nephrology	15 (12.4%)	121
	• Endocrinology	3 (2.5%)	121
	• Emergency	19 (15.7%)	121
	• Dermatology	15 (12.4%)	121
	• Other	19 (15.7%)	121
	Time elapsed since above-goal LDLc value	47 months (IQR 24-97)	252 (subgroup of patients whose most recently documented LDLc

			value in the chart was above the newly recommended goals, i.e., red in Figure 1A)
Assessments of levels of glycated hemoglobin (HbA$_{1c}$)			
	HbA$_{1c}$ checked at least once	208 (56.2%)	370 (entire LE-ASCVD Study Cohort)
	Time elapsed since the most recently documented HbA$_{1c}$ assay	36 months (IQR 11-68)	208 (subgroup with at least one HbA$_{1c}$ value in the chart)
	PCP checked the most recent HbA$_{1c}$	132 (65.3%)	202
	Non-PCPs checked the most recent HbA$_{1c}$	70 (34.7%)	202
	• Rheumatology	18 (25.7%)	70 (subgroup for whom non-PCPs checked the most recent HbA$_{1c}$)
	• Cardiology	14 (20.0%)	70
	• Nephrology	2 (2.9%)	70
	• Endocrinology	3 (4.3%)	70
	• Emergency	12 (17.1%)	70
	• Dermatology	9 (12.9%)	70
	• Other	12 (17.1%)	70
	Time elapsed since abnormal HbA$_{1c}$ value	48 months (IQR 24-80)	89 (subgroup of patients whose most recently documented HbA$_{1c}$ value in the chart was abnormal, meaning ≥5.7%)

980
981

Supplementary Figure S1. Assessment and management of plasma non-high-density lipoprotein cholesterol (non-HDLc) concentrations in the LE-ASCVD Study Cohort. <u>Panel A</u>: Classification of Study Cohort patients into the four categories of ASCVD event risk defined by the newly proposed guidelines of Keyes et al. for lupus patients.[1] Also indicated are numbers of patients with non-HDLc levels above (red) or within (green) the newly proposed goals for each risk category. Patients without an available non-HDLc value (or no simultaneous total cholesterol and HDLc) are indicated in blue. <u>Panel B</u>: Absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic charts of patients classified into each of the four newly proposed categories of ASCVD event risk for lupus patients and whose most recent plasma non-HDLc levels were above the newly proposed goals; these are the patients indicated in red in panel S1A. <u>Panel C</u>: Estimated risk of an ASCVD event in the next 10 years ("10-year ASCVD event risk") by the online ACC Risk Estimator Plus and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. Patients are grouped according to the cut-offs for estimated 10-year ASCVD event risk from the ACC/AHA Guideline on primary prevention (0.0-4.9%, 5.0-7.4%, &c).[25] As noted in the Methods and in Figure 1, patients below age 40 years without clinically evident ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus (n=47/370) were scaled up to 40, and patients above age 79 years without clinically evident ASCVD (n=13/370) were scaled down to 79. Data are presented with these additional patients included (Figure 1C) or presented separately (here). Also shown here are data for patients with clinically evident ASCVD (secondary prevention, for which the ACC ASCVD Risk Estimator Plus does not apply), as well as data for patients with no clinically evident ASCVD but insufficient information in the electronic chart for the ACC Risk Estimator (rightmost column). <u>Panel D</u>: Most recent non-HDLc values and absence (red) or presence (green) of an active prescription for an LDL-lowering medication. The rightmost column represents patients with no non-HDLc value (or no simultaneous total cholesterol and HDLc) in the electronic chart. At the top of each column in panels A-D is indicated the total number of patients represented by that column. Numbers of patients represented by each tinted portion of each column are also given.

1029
1030

1031
1032
1033

1034
1035

Supplementary Figure S2. Three systems to estimate the risk of a future ASCVD event for individual patients in the LE-ASCVD Study Cohort, as described in Figure 3. Data are shown for the subset of patients in the Study Cohort for whom both online calculators could be used, meaning no clinically evident ASCVD (primary prevention) and sufficient data in the electronic charts to allow use of these online tools. P-values were calculated with linear regression. Panel A: Presentation of data with (Figure 3A, n=254) and without (here, n=194) age scaling for the ACC ASCVD Risk Estimator Plus. Each dot represents an individual patient. Blue dots indicate patients classified at "High Risk" (n=31/194), and yellow dots indicate patients classified at "Very High Risk" (n=163/194) according to Keyes et al.[1] The horizontal and vertical dashed gray lines indicate the key cut-off of 7.5% estimated 10-year ASCVD event risk from Arnett et al. 2019,[25] for each of the two calculators. As in Fig. 3A, Pearson's linear correlation was used to test the statistical relationship between the two numerical estimates of 10-year ASCVD event risk, and the calculated regression line is indicated in dashed red with key parameters given on the right. Panel B: Clinically meaningful agreement (green) and discordance (red, white) amongst the three systems for estimating the risk of a future ASCVD event for individual patients in the LE-ASCVD Study Cohort; this panel is same as Figure 3D but does not include patients whose ages were scaled to allow use of the ACC ASCVD Risk Estimator Plus.

A

r²=0.4612, , n=194
p-value=1.3956×10⁻²⁷
y = 0.8765 x + 7.6674

1054
1055
1056

1057

1058
1059
1060

Supplementary Figure S3. Cumulative incidence of documented major adverse atherosclerotic
cardiovascular events (MAACE) in the LE-ASCVD Study Cohort. The 17 events that were
documented before enrollment in the LE-ASCVD Study Cohort occurred in 17 lupus patients
and are indicated at time 0 (n=17/370, 4.59%). For all patients, the first MAACE after
enrollment was counted for this curve (time >0) but no subsequent MAACE. After enrollment,
the numbers of patients in the Cohort year by year are consistently higher than the numbers at
risk in the Kaplan-Meier curve of event-free survival (Figure 4), because when a patient has a
non-fatal event, he or she becomes censored from the K-M curve, but still remains in the Cohort.
1069

1070
1071
1072